Patent · US Active

Engineered cleavage half-domains

US8962281B2 · kind B2 · utility

55Cited by

18References

20Claims

0Family size

Assignee

Sangamo Biosciences, Inc. · US

Inventors

Yannick Doyon · Brisbane, US
Jeffrey C. Miller · Pleasanton, US

Key dates

Filing date	Feb 7, 2011
Grant date	Feb 24, 2015
Priority date	—
Expiry date	Feb 28, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y301/21004
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.